文献速递肿瘤 PET/CT放射性药物与辐射防护

多西他赛致间质性肺炎在68Ga-PSMA PET/CT上的检出

Docetaxel-Induced Interstitial Pneumonitis Detected on 68Ga-PSMA PET/CT.
PubMed 文献 · Clin Nucl Med · 2021-01-01

本文报道一例转移性去势抵抗性前列腺癌患者,在接受多西他赛治疗后,于68Ga-PSMA PET/CT上检出多西他赛诱导的间质性肺炎。文中指出68Ga-PSMA PET/CT常用于生化复发后中高危前列腺癌分期,且良性病变也可出现68Ga-PSMA摄取;多西他赛主要治疗不良反应包括骨髓抑制、脱发和乏力,间质性肺炎见于不足2%的多西他赛治疗患者。

要点

  • 68Ga-PSMA PET/CT可用于检出多西他赛诱导的间质性肺炎。
  • 多西他赛治疗患者中间质性肺炎发生率不足2%。
  • 68Ga-PSMA在良性病变中也可出现摄取,需注意鉴别。

核心结论

  • 多西他赛诱导的间质性肺炎可在68Ga-PSMA PET/CT上被检出。

研究设计与样本

  • 本文为个案报道,对象为一例转移性去势抵抗性前列腺癌患者。

主要发现

  • 该患者在多西他赛治疗后,68Ga-PSMA PET/CT检出多西他赛诱导的间质性肺炎。

关键数值与推荐

  • 间质性肺炎见于不足2%的多西他赛治疗患者。
  • 多西他赛主要治疗相关不良反应包括骨髓抑制、脱发和乏力。

临床怎么用

  • 前列腺癌患者多西他赛治疗后行68Ga-PSMA PET/CT时,应关注间质性肺炎的可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

68Ga-PSMA PET/CT is a commonly performed procedure in the staging of intermediate- and high-risk prostate cancer after biochemical recurrence. Uptake of 68Ga-PSMA in benign conditions is also reported in the literature. Docetaxel is the mainstay of treatment in high-volume hormone-sensitive prostate cancer and castration-resistant prostate cancer. The major treatment-emergent adverse drug reactions attributed to docetaxel include myelosuppression, alopecia, and asthenia. Interstitial pneumonitis is seen in less than 2% of docetaxel-treated patients. We present a case of metastatic castration-resistant prostate cancer, wherein docetaxel-induced interstitial pneumonitis was detected on 68Ga-PSMA PET/CT, after docetaxel treatment.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kumar S, Singh H, Das CK, et al. Docetaxel-Induced Interstitial Pneumonitis Detected on 68Ga-PSMA PET/CT. Clin Nucl Med. 2021. PMID: 33315676. doi:10.1097/RLU.0000000000003445

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。